Metabolic Syndrome and Insulin Resistance in Sodium Valproate or Carbamazepine Monotherapy: A Case-control Study

Document Type : Original Article

Authors

1 Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran & Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran

3 Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran & Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Medications can increase the incidence rate of metabolic syndrome (MetS) and insulin resistance (IR). This study aimed to evaluate the effects of Carbamazepine (CBZ) or Valproate (VPA) as monotherapy on the development of MetS and IR in adult Iranian epileptic patients.
Methods: In this observational analytic case-control study, 80 epileptic patients were treated with VPA (40 patients) or CBZ (40 patients) monotherapies for more than 6 months, and 45 age- and sex-matched controls were included.
Results: Subjects with MetS or with IR had higher age, weight, waist, FBS, cholesterol, systolic and diastolic pressure, TG, LDL, insulin, BMI, and lower HDL. In MetS and IR, the frequency of VPA or CBZ use was significantly higher than the control group. The multiple regression analysis showed that in VPA-treated epileptic patients, the risk of MetS was increased 19 times higher than controls (OR= 19.20; 95% CI= 2.62-140.23, P=0. 004) and risk of IR was increased 15 and 9 times more than controls (OR=14.83; 95% CI=3.03-72.56, P=0.001) and (OR=9.13; 95% CI=2.55-32.65, P= 0.001), respectively. An increase in the waist, DBP, and insulin level were also shown as important factors in the risk of MetS. In patients under CBZ therapy, the risk of MetS reduced by 17% less than controls and the risk of IR increased 7 times more than controls.
Conclusion: Treatment with VPA may increase the likelihood of developing MetS and IR more than the CBZ therapy in epileptic patients in Iran.

Keywords


  1. Rakitin A, Eglit T, Koks S, Lember M, Haldre S. Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia. PLoS One. 2014; 9(7):e103856. doi: 10.1371/journal.pone.0103856.
  2. Rakitin A, Koks S, Haldre S. Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine. Seizure. 2016; 38:11-6. doi: 10.1016/j.seizure.2016.03.008.
  3. Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc). 2005; 41(8):547-55. doi: 10.1358/dot.2005.41.8.893630.
  4. Gaspari CN, Guerreiro CA. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr. 2010; 68(2):277-81. doi: 10.1590/
    s0004-282x2010000200024.
  5. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an american heart association scientific statement from the atherosclerosis, hypertension, and obesity in the young committee (council on cardiovascular disease in the young) and the diabetes committee (council on nutrition, physical activity, and metabolism). Circulation. 2003; 107(10):1448-53. doi: 10.1161/01.
    0000060923.07573.f2. 
  6. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993; 44:121-31. doi: 10.1146/annurev
    .me.44.020193.001005.
  7. Rask Larsen J, Dima L, Correll CU, Manu P. The pharmacological management of metabolic syndrome. Expert Rev Clin Pharmacol. 2018; 11(4):397-410. doi: 10.1080/17512433.2018.1429910. 
  8. Repousi N, Masana MF, Sanchez-Niubo A, Haro JM, Tyrovolas S. Depression and metabolic syndrome in the older population: A review of evidence. J Affect Disord. 2018; 237:56-64. doi: 10.1016/j.jad.2018.04.
  9. Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia. 2007; 48(7):1366-70. doi: 10.1111/j.1528-1167.2007.01052.x.
  10. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002; 360(9340):1155-62. doi: 10.1016/S0140-6736(02)11203-7.
  11. Luef G, Abraham I, Haslinger M, Trinka E, Seppi K, Unterberger I, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol. 2002; 249(7):835-41. doi: 10.1007/s00415-002-0731-3. 
  12. Katsiki N, Mikhailidis DP, Nair DR. The effects of antiepileptic drugs on vascular risk factors: a narrative review. Seizure. 2014; 23(9):677-84. doi: 10.1016/
    seizure.2014.05.011.
  13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25; 112(17):2735-52. doi: 10.1161/CIRCULATIONAHA.
    169404. 
  14. Najafi MR, Bazooyar B, Zare M, Aghaghazvini MR, Ansari B, Rajaei A, et al. The investigation of insulin resistance in two groups of epileptic patients treated with sodium valproate and carbamazepine. Adv Biomed Res. 2017; 6:25. doi: 10.4103/2277-9175.
  15. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics. 1999; 103(3):588-93. doi: 10.1542/peds.103.3.588.
  16. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366(9491):1059-62. doi: 10.1016/S0140-6736(05)67402-8. 
  17. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012; 16(1):7-12. doi: 10.4103/2230-8210.91175. 
  18. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015; 19(1):160-4. doi: 10.4103/2230-8210.146874.
  19. Kim TJ, Kim HJ, Kim YB, Lee JY, Lee HS, Hong JH, et al. Comparison of surrogate markers as measures of uncomplicated insulin resistance in Korean adults. Korean J Fam Med. 2016; 37(3):188-96. doi:
    4082/kjfm.2016.37.3.188.
  20. Sonmez FM, Zaman D, Aksoy A, Deger O, Aliyazicioglu R, Karaguzel G, et al. The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy. Seizure. 2013; 22(10):856-61. doi: 10.1016/j.seizure.2013.07.007. 
  21. Calandre EP, Dominguez-Granados R, Gomez-Rubio M, Molina-Font JA. Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurol Scand. 1990; 81(6):504-6. doi: 10.1111/j.1600-0404.1990.tb01008.x. 
  22. Saleh DA, Ismail MA, Ibrahim AM. Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy. Pak J Biol Sci. 2012; 15(2):68-77. doi: 10.3923/pjbs.2012.68.77. 
  23. Verrotti A, Di Marco G, la Torre R, Pelliccia P, Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr. 2009; 168(11):1391-4. doi: 10.1007/s00431-009-0927-y. 
  24. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics. 1998; 29(4):195-201. doi: 10.1055/s-2007-973560. 
  25. Verrotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010; 51(2):268-73. doi: 10.1111/j.1528-1167.2009.02206.x.
  26. Nair SS, Harikrishnan S, Sarma PS, Thomas SV. Metabolic syndrome in young adults with epilepsy. Seizure. 2016; 37:61-4. doi: 10.1016/j.seizure.2016.
    002. 
  27. Cabral LS, Cherubini PA, de Oliveira MA, Bianchini L, Torres CM, Bianchin MM. Diagnostic yield and accuracy of different metabolic syndrome criteria in adult patients with epilepsy. Front Neurol. 2017; 8:460. doi: 10.3389/fneur.2017.00460.
  28. Sudhop T, Bauer J, Elger CE, von Bergmann K. Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia. 1999; 40(4):480-4. doi: 10.1111/j.1528-1157.1999.tb00744.x.
  29. Brites F, Martin M, Guillas I, Kontush A. Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clin. 2017; 8:66-77. doi: 10.1016/j.bbacli.2017.07.002.
  30. Vyas MV, Davidson BA, Escalaya L, Costella J, Saposnik G, Burneo JG. Antiepileptic drug use for treatment of epilepsy and dyslipidemia: Systematic review. Epilepsy Res. 2015; 113:44-67. doi: 10.1016/j.
    2015.03.002.
  31. Pylvanen V, Knip M, Pakarinen AJ, Turkka J, Kotila M, Rattya J, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology. 2003; 60(4):571-4. doi: 10.1212/01.wnl.0000048209.07526.
  32. Fang J, Chen S, Tong N, Chen L, An D, Mu J, et al. Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate. Seizure. 2012; 21(8):578-82. doi: 10.1016/j.seizure.2012.06.001. 
  33. Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav. 2006; 8(3):643-8. doi: 10.1016/j.yebeh.2006.02.008.
  34. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001; 42(8):1002-6. doi: 10.1046/j.1528-1157.2001.0420081002.x. 
  35. Dolab N, Kamkar MZ, Amiriani T, Yuzugulen J, Marjani M, Marjani A. The association between leptin and adiponectin, and metabolic syndrome components and serum levels of lipid peroxidation in bipolar disorder patients treated with lithium and valproic Heliyon. 2020; 6(7):e04553. doi: 10.1016/j.heliyon.
    2020.e04553. 
  36. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt Sinai J Med. 2010; 77(5):511-23. doi: 10.1002/msj.20212.
  37. Kwan P, Yip FP, Hui AC, Leung H, Ng PW, Hui KF, et al. Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: a prospective randomized study. Epilepsy Behav. 2009; 14(4):610-6. doi: 10.1016/j.yebeh.2009.01.010.
  38. Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in Valproate-treated patients with epilepsy. Epilepsia. 2006; 47(9):1460-4. doi: 10.1111/j.1528-1167.2006.00546.x.
  39. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest. 1975; 55(6):1278-83. doi: 10.1172/
  40. Nisha Y, Bobby Z, Wadwekar V. Biochemical derangements related to metabolic syndrome in epileptic patients on treatment with valproic acid. Seizure. 2018; 60:57-60. doi: 10.1016/j.seizure.2018.
    003. 
  41. Chuang YC, Chuang HY, Lin TK, Chang CC, Lu CH, Chang WN, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012; 53(1):120-8. doi: 10.1111/j.1528-1167.2011.03316.x.